Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation

Biochemical and Biophysical Research Communications

Volumn 427, Issue 2, 2012, Pages 404-409

  Zawawi, M S F ^a,b   Dharmapatni, A A S S K ^b   Cantley, M D ^b   McHugh, K P ^c   Haynes, D R ^b   Crotti, T N ^b  

^a SCHOOL OF PHYSICS   (Malaysia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

3 Integrin; Annexin VIII; Calcineurin; FK506; ITAM; NFATc1; Osteoclast; VIVIT

Indexed keywords

BETA3 INTEGRIN; CALCINEURIN; CATHEPSIN K; COLONY STIMULATING FACTOR RECEPTOR; FC RECEPTOR; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MEMBRANE RECEPTOR; OSTEOCLAST ASSOCIATED RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM SIGNALING; CELL ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CALCINEURIN; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION; HUMANS; IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF; MEMBRANE GLYCOPROTEINS; NFATC TRANSCRIPTION FACTORS; OLIGOPEPTIDES; OSTEOCLASTS; RECEPTORS, CELL SURFACE; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; TACROLIMUS;

EID: 84867873622     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.077     Document Type: Article

References (38)

1. Gravallese E.M., Harada Y., Wang J.T., Gorn A.H., Thornhill T.S., Goldring S.R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 1998, 152:943-951.
2. Shen Z., Crotti T.N., McHugh K.P., Matsuzaki K., Gravallese E.M., Bierbaum B.E., Goldring S.R. The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis. Arthritis Res. Ther. 2006, 8:R70.
3. Crotti T., Smith M.D., Hirsch R., Soukoulis S., Weedon H., Capone M., Ahern M.J., Haynes D. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J. Periodontal. Res. 2003, 38:380-387.
4. Crotti T.N., Smith M.D., Findlay D.M., Zreiqat H., Ahern M.J., Weedon H., Hatzinikolous G., Capone M., Holding C., Haynes D.R. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB RANK ligand and osteoprotegerin. Biomaterials 2004, 25:565-573.
5. Crotti T.N., Smith M.D., Weedon H., Ahern M.J., Findlay D.M., Kraan M., Tak P.P., Haynes D.R. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann. Rheum. Dis. 2002, 61:1047-1054.
6. Hirotani H., Tuohy N.A., Woo J.T., Stern P.H., Clipstone N.A. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem. 2004, 279:13984-13992.
7. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., Crabtree G.R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997, 275:1930-1934.
8. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., Kodama T., Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002, 3:889-901.
9. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., Morita I., Wagner E.F., Mak T.W., Serfling E., Takayanagi H. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 2005, 202:1261-1269.
10. Kim Y., Sato K., Asagiri M., Morita I., Soma K., Takayanagi H. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J. Biol. Chem. 2005, 280:32905-32913.
11. Crotti T.N., Flannery M., Walsh N.C., Fleming J.D., Goldring S.R., McHugh K.P. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 2006, 372:92-102.
12. Ishida N., Hayashi K., Hoshijima M., Ogawa T., Koga S., Miyatake Y., Kumegawa M., Kimura T., Takeya T. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 2002, 277:41147-41156.
13. Crotti T.N., Sharma S.M., Fleming J.D., Flannery M.R., Ostrowski M.C., Goldring S.R., McHugh K.P. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J. Cell. Physiol. 2008, 215:636-644.
14. Kim K., Kim J.H., Lee J., Jin H.M., Lee S.H., Fisher D.E., Kook H., Kim K.K., Choi Y., Kim N. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J. Biol. Chem. 2005, 280:35209-35216.
15. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., Hisatake K., Nogi Y. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 2004, 279:45969-45979.
16. Crotti T.N., O'Sullivan R.P., Shen Z., Flannery M.R., Fajardo R.J., Ross F.P., Goldring S.R., McHugh K.P. Bone matrix regulates osteoclast differentiation and annexin A8 gene expression. J. Cell. Physiol. 2011.
17. Ishikawa S., Arase N., Suenaga T., Saita Y., Noda M., Kuriyama T., Arase H., Saito T. Involvement of FcRgamma in signal transduction of osteoclast-associated receptor(OSCAR). Int. Immunol. 2004, 16:1019-1025.
18. Takayanagi H. The role of NFAT in osteoclast formation. Ann. N. Y. Acad. Sci. 2007, 1116:227-237.
19. Alias E., Dharmapatni A.S., Holding A.C., Atkins G.J., Findlay D.M., Howie D.W., Crotti T.N., Haynes D.R. Polyethylene particles stimulate expression of ITAM-related molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomater. 2012.
20. Paloneva J., Mandelin J., Kiialainen A., Bohling T., Prudlo J., Hakola P., Haltia M., Konttinen Y.T., Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J. Exp. Med. 2003, 198:669-675.
21. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., Iwata T., Ohnishi H., Matozaki T., Kodama T., Taniguchi T., Takayanagi H., Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
22. A. Mocsai, M.B. Humphrey, J.A. Van Ziffle, Y. Hu, A. Burghardt, S.C. Spusta, S. Majumdar, L.L. Lanier, C.A. Lowell, M.C. Nakamura, The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase, Proc. Natl. Acad. Sci. USA 101 (2004) 6158-6163.
23. Kim G.S., Koh J.M., Chang J.S., Park B.L., Kim L.H., Park E.K., Kim S.Y., Shin H.D. Association of the OSCAR promoter polymorphism with BMD in postmenopausal women. J. Bone miner. Res.: official J. Am. Soc. Bone Miner. Res. 2005, 20:1342-1348.
24. Herman S., Muller R.B., Kronke G., Zwerina J., Redlich K., Hueber A.J., Gelse H., Neumann E., Muller-Ladner U., Schett G. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum. 2008, 58:3041-3050.
25. Zhao S., Guo Y.Y., Ding N., Yang L.L., Zhang N. Changes in serum levels of soluble osteoclast-associated receptor in human rheumatoid arthritis. Chin. Med. J. 2011, 124:3058-3060.
26. Y.H. Lee, J.H. Woo, S.J. Choi, J.D. Ji, S.C. Bae, G.G. Song, Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials, Scand. J. Rheumatol. 39 (2010) 271-278.
27. Miyazaki M., Fujikawa Y., Takita C., Tsumura H. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin. Rheumatol. 2007, 26:231-239.
28. Yamanaka Y., Abu-Amer W., Foglia D., Otero J., Clohisy J.C., Abu-Amer Y. NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis. J. Orthop. Res. 2008, 26:1577-1584.
29. Yeo H., McDonald J.M., Zayzafoon M. NFATc1: a novel anabolic therapeutic target for osteoporosis. Ann. N. Y. Acad. Sci. 2006, 1068:564-567.
30. Yu H., van Berkel T.J., Biessen E.A. Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders. Cardiovasc. Drug Rev. 2007, 25:175-187.
31. Aramburu J., Yaffe M.B., Lopez-Rodriguez C., Cantley L.C., Hogan P.G., Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999, 285:2129-2133.
32. Liu F., Zhu Z., Mao Y., Liu M., Tang T., Qiu S. Inhibition of titanium particle-induced osteoclastogenesis through inactivation of NFATc1 by VIVIT peptide. Biomaterials 2009, 30:1756-1762.
33. Cantley M.D., Fairlie D.P., Bartold P.M., Rainsford K.D., Le G.T., Lucke A.J., Holding C.A., Haynes D.R. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J. Cell. Physiol. 2011, 226:3233-3241.
34. Franssen M.E., Zeeuwen P.L., Vierwinden G., van de Kerkhof P.C., Schalkwijk J., van Erp P.E. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J. Invest. Dermatol. 2005, 124:373-383.
35. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
36. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) 1987, 40:1256-1265.
37. Zou W., Kitaura H., Reeve J., Long F., Tybulewicz V.L., Shattil S.J., Ginsberg M.H., Ross F.P., Teitelbaum S.L. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell Biol. 2007, 176:877-888.
38. Teitelbaum S.L. The osteoclast and its unique cytoskeleton. Ann. N. Y. Acad. Sci. 2011, 1240:14-17.